|
Systolic Pressure
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation.
|
27841878 |
2017 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
The predictors (autoantibodies to HCC1, P16, P53, P90, and survivin) indicated the presence of HCC prior to diagnosis in 16 of the 17 patients, at a median lead time of 0.75 year.
|
29497780 |
2018 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Collectively, these results indicate that LEF1-upregulated miR-HCC1 functions as an oncogene through the negative regulation of NFIX expression, which links the LEF1/miR-HCC1/NFIX axis to contribute to cell proliferation, migration and invasion of HCC cells and could provide novel insights into miRNA function and hepatocarcinogenesis and potential biomarkers for HCC.
|
29472529 |
2018 |
|
Liver carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
We measured PCDH18 expression level in eight HCC cell lines as well as HCC1 and HCC2 by real-time quantitative RT-PCR.
|
29075151 |
2017 |
|
Liver carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
A novel protein, Hcc-1, was identified by analysis of the hepatocellular carcinoma (HCC)-M cell proteome.
|
11356193 |
2001 |
|
Cholangiocarcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The 15-patient cohort (17 cases from 2015 to 2018) included those diagnosed with liver tumors (14 hepatocellular carcinoma, 1 cholangiocarcinoma, 1 renal-cell carcinoma, and 1 metastatic colorectal carcinoma) and chosen for radioembolization via a multimodal approach.
|
31155499 |
2019 |
|
Hepatitis C
|
0.020 |
Biomarker
|
disease |
BEFREE |
In this cohort, 35 patients (18.7%) were HCV core antigen (Ag)-positive, and 13 of them (37.1%) died (due to liver cirrhosis (4 cases), hepatocellular carcinoma (1 case), fibrosing cholestatic hepatitis due to HCV (1 case), and infections complicated with chronic hepatitis (6 cases)).
|
28357506 |
2017 |
|
Cholangiocarcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Of the enrolled patients, 2 were diagnosed with hepatocellular carcinoma, 1 with cholangiocellular carcinoma, 1 with liver metastasis, 2 with pancreatic ductal adenocarcinoma, 1 with renal cell carcinoma and 1 with malignant lymphoma.
|
29042975 |
2017 |
|
Malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
When cutoff values were set as mean optical density values plus 3 standard deviation of normal controls, the positive rate of autoantibodies against four tumor-associated antigens (Survivin, Cyclin B1, HCC1, and p53) reached 32%, 20%, 22%, and 18%, with area under the curve values of 0.653, 0.767, 0.622, and 0.623 in sera from 50 lung cancer, respectively (all p < 0.05).
|
29022480 |
2017 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
When cutoff values were set as mean optical density values plus 3 standard deviation of normal controls, the positive rate of autoantibodies against four tumor-associated antigens (Survivin, Cyclin B1, HCC1, and p53) reached 32%, 20%, 22%, and 18%, with area under the curve values of 0.653, 0.767, 0.622, and 0.623 in sera from 50 lung cancer, respectively (all p < 0.05).
|
29022480 |
2017 |
|
Primary malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
When cutoff values were set as mean optical density values plus 3 standard deviation of normal controls, the positive rate of autoantibodies against four tumor-associated antigens (Survivin, Cyclin B1, HCC1, and p53) reached 32%, 20%, 22%, and 18%, with area under the curve values of 0.653, 0.767, 0.622, and 0.623 in sera from 50 lung cancer, respectively (all p < 0.05).
|
29022480 |
2017 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
HCC1/CAPERα is considered to be a novel human tumor-associated antigen, and the tumor-specific immunity of HCC1/CAPERα has been reported in several types of cancer.
|
24643682 |
2014 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 1. Flt3 ligand gene transfer increases antitumor effects of a radio-inducible suicide gene therapy in an ectopic tumor model.
|
24972258 |
2014 |
|
Malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our data suggest that overexpression of HCC1/CAPERα may increase the proliferation and migration of NSCLC cells, and HCC1/CAPERα could be a promising biomarker for lung cancer.
|
24643682 |
2014 |
|
Carcinoma of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our data suggest that overexpression of HCC1/CAPERα may increase the proliferation and migration of NSCLC cells, and HCC1/CAPERα could be a promising biomarker for lung cancer.
|
24643682 |
2014 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
HCC1/CAPERα is considered to be a novel human tumor-associated antigen, and the tumor-specific immunity of HCC1/CAPERα has been reported in several types of cancer.
|
24643682 |
2014 |
|
Primary malignant neoplasm of lung
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our data suggest that overexpression of HCC1/CAPERα may increase the proliferation and migration of NSCLC cells, and HCC1/CAPERα could be a promising biomarker for lung cancer.
|
24643682 |
2014 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The primary cell populations (hcc-1, -2 and -3) and two clones generated by means of limiting dilutions from hcc-1 (clone-1/7 and -1/8) differently expressed a number of tumour-associated stem cell markers, including EpCAM, CD49f, CD44, CD133, CD56, Thy-1, ALDH and CK19, and also showed different doubling times, drug resistance and tumorigenic potential.
|
21731718 |
2011 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Eight patients had died at the time of their entry into the Registry; 2 of pneumonia (1 P. carinii and 1 cytomegalovirus), 2 of encephalitis (1 ECHO virus and 1 cytomegalovirus), 2 of malignancy (both hepatocellular carcinoma), 1 of sclerosing cholangitis caused by Cryptosporidium, and 1 of hemolytic uremic syndrome.
|
14663287 |
2003 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
Eight patients had died at the time of their entry into the Registry; 2 of pneumonia (1 P. carinii and 1 cytomegalovirus), 2 of encephalitis (1 ECHO virus and 1 cytomegalovirus), 2 of malignancy (both hepatocellular carcinoma), 1 of sclerosing cholangitis caused by Cryptosporidium, and 1 of hemolytic uremic syndrome.
|
14663287 |
2003 |
|
Hepatitis C
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Evaluation of serum samples with different status of HBV and HCV infections suggested that HCc(1-98) might be suitable for the determination of antibodies against HCV core protein, while HBcPreS1PreS2HCc(1-98) might be of value to detect HCV and/or HBV infection in donated blood in HBV low-prevalence countries.
|
9892392 |
1999 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the role of SARNP in mRNA splicing and export and in the progression of breast cancer, especially of TNBC, remains unknown.
|
31313837 |
2020 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
However, the role of SARNP in mRNA splicing and export and in the progression of breast cancer, especially of TNBC, remains unknown.
|
31313837 |
2020 |
|
Triple Negative Breast Neoplasms
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we examined the role of SARNP in mRNA splicing and export and progression of TNBC.
|
31313837 |
2020 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we examined the role of SARNP in mRNA splicing and export and progression of TNBC.
|
31313837 |
2020 |